Omnicell (NASDAQ:OMCL) Downgraded by StockNews.com to “Hold”

Omnicell (NASDAQ:OMCL) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued on Monday.

Several other brokerages have also recently weighed in on OMCL. Wells Fargo & Company decreased their price objective on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Bank of America decreased their price target on Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a research report on Monday, January 6th. JPMorgan Chase & Co. cut their price objective on Omnicell from $44.00 to $36.00 and set a “neutral” rating for the company in a research report on Thursday, March 20th. Finally, Benchmark restated a “buy” rating and set a $62.00 target price on shares of Omnicell in a report on Tuesday, February 4th. Five equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, Omnicell presently has an average rating of “Hold” and a consensus price target of $51.00.

Omnicell Stock Performance

Shares of NASDAQ OMCL opened at $34.47 on Monday. Omnicell has a one year low of $25.12 and a one year high of $55.75. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13. The business has a fifty day simple moving average of $39.47 and a 200 day simple moving average of $42.75. The firm has a market capitalization of $1.61 billion, a price-to-earnings ratio of 127.67, a PEG ratio of 7.53 and a beta of 0.85.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. Sell-side analysts expect that Omnicell will post 1.09 EPS for the current year.

Institutional Investors Weigh In On Omnicell

A number of hedge funds and other institutional investors have recently made changes to their positions in OMCL. Smartleaf Asset Management LLC raised its stake in shares of Omnicell by 51.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 803 shares of the company’s stock valued at $35,000 after purchasing an additional 273 shares during the period. Johnson Financial Group Inc. bought a new position in shares of Omnicell during the fourth quarter worth about $37,000. Van ECK Associates Corp raised its position in Omnicell by 47.0% in the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock valued at $44,000 after buying an additional 315 shares during the last quarter. Headlands Technologies LLC bought a new stake in Omnicell in the 4th quarter valued at approximately $53,000. Finally, First Horizon Advisors Inc. boosted its position in Omnicell by 36.3% during the 4th quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock worth $59,000 after acquiring an additional 355 shares during the last quarter. 97.70% of the stock is currently owned by institutional investors and hedge funds.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.